- Home
- ALAR vs SPRO Comparison
ALAR vs SPRO Comparison
Compare ALAR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- SPRO
- Stock Information
- Founded
- ALAR 2013
- SPRO 2013
- Country
- ALAR Israel
- SPRO United States
- Employees
- ALAR N/A
- SPRO N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- ALAR Technology
- SPRO Health Care
- Exchange
- ALAR Nasdaq
- SPRO Nasdaq
- Market Cap
- ALAR 116.1M
- SPRO 107.5M
- IPO Year
- ALAR 2018
- SPRO 2017
- Fundamental
- Price
- ALAR $16.55
- SPRO $1.87
- Analyst Decision
- ALAR Strong Buy
- SPRO Buy
- Analyst Count
- ALAR 1
- SPRO 4
- Target Price
- ALAR $15.00
- SPRO $5.00
- AVG Volume (30 Days)
- ALAR 90.6K
- SPRO 798.2K
- Earning Date
- ALAR 08-28-2025
- SPRO 08-12-2025
- Dividend Yield
- ALAR N/A
- SPRO N/A
- EPS Growth
- ALAR N/A
- SPRO N/A
- EPS
- ALAR 0.07
- SPRO N/A
- Revenue
- ALAR $30,581,000.00
- SPRO $48,576,000.00
- Revenue This Year
- ALAR $11.54
- SPRO N/A
- Revenue Next Year
- ALAR $19.42
- SPRO N/A
- P/E Ratio
- ALAR $24.94
- SPRO N/A
- Revenue Growth
- ALAR 4.67
- SPRO N/A
- 52 Week Low
- ALAR $5.45
- SPRO $0.51
- 52 Week High
- ALAR $22.44
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- ALAR 66.68
- SPRO 35.23
- Support Level
- ALAR $15.65
- SPRO $1.80
- Resistance Level
- ALAR $17.27
- SPRO $2.38
- Average True Range (ATR)
- ALAR 0.92
- SPRO 0.12
- MACD
- ALAR 0.11
- SPRO -0.02
- Stochastic Oscillator
- ALAR 83.56
- SPRO 12.07
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.